Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:47:43 EDT Fri 03 Oct 2025
Enter Symbol
or Name
USA
CA



Q:CYDY - CYTODYN INC - https://www.cytodyn.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYDY - Qnot subscribed0.26-0.00302-1.1799.51982020.262  0.265  0.25120.4945  0.103116:00:00Sep 3015 min RT 2¢

Recent Trades - Last 10 of 202
Time ETExPriceChangeVolume
16:00:00Q0.26-0.003021,000
15:59:57Q0.2595-0.003521,000
15:59:18Q0.2595-0.0035222
15:58:02Q0.26-0.003023,157
15:57:36Q0.259-0.004025,000
15:57:12Q0.2598-0.0032217
15:56:28Q0.2591-0.0039221
15:55:55Q0.26-0.003021,000
15:55:42Q0.2595-0.0035245
15:55:00Q0.2595-0.003523,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-09-30 08:31U:CYDYNews ReleaseSeptember 2025 Letter to Shareholders
2025-09-25 08:30U:CYDYNews ReleaseCytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
2025-09-16 08:30U:CYDYNews ReleaseCytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
2025-09-04 08:30U:CYDYNews ReleaseCytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
2025-08-28 08:30U:CYDYNews ReleaseCytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
2025-07-01 08:30U:CYDYNews ReleaseCytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
2025-06-24 08:30U:CYDYNews ReleaseCytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
2025-05-15 08:30U:CYDYNews ReleaseCytoDyn Releases ESMO Breast Cancer Meeting Poster
2025-05-13 08:30U:CYDYNews ReleaseCytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
2025-05-06 08:30U:CYDYNews ReleaseCytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
2025-04-29 08:30U:CYDYNews ReleaseCytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
2025-03-18 08:30U:CYDYNews ReleaseMarch 2025 Letter to Shareholders
2025-02-24 08:30U:CYDYNews ReleaseCytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
2025-02-06 08:30U:CYDYNews ReleaseCytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
2024-12-17 08:30U:CYDYNews ReleaseDecember 2024 Letter to Shareholders
2024-11-25 08:30U:CYDYNews ReleaseCytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
2024-11-04 08:30U:CYDYNews ReleaseCytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
2024-10-30 08:30U:CYDYNews ReleaseCytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
2024-10-08 08:30U:CYDYNews ReleaseCytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
2024-10-07 11:05U:CYDYNews ReleaseCytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques